Antiarrhythmic drugs and epilepsy.

Area of Science:

• Neuroscience
• Pharmacology
• Cardiology

Background:

• Epilepsy and cardiac arrhythmia share suspected common molecular pathways.
• Seizures can disrupt central autonomic control, altering cardiac rhythm and potentially leading to sudden unexpected death in epilepsy (SUDEP).
• Shared pathogenesis suggests antiarrhythmic drugs (AADs) may influence seizure activity and interact with antiepileptic drugs (AEDs).

Purpose of the Study:

• To review the anticonvulsant and proconvulsant effects of various classes of AADs.
• To explore the potential interactions between AADs and AEDs.
• To understand the implications for treating patients with co-occurring epilepsy and cardiac conditions.

Main Methods:

• Review of existing literature on AADs and their effects on seizure models and patients.
• Analysis of anticonvulsant activities of different AAD classes (I-IV) in various epilepsy models.
• Examination of AAD interactions with AEDs in experimental and clinical settings.

Main Results:

• Class I AADs: Phenytoin is an established AED; lidocaine and mexiletine show anticonvulsant activity.
• Class II AADs (beta-blockers): Propranolol, metoprolol, pindolol, and timolol demonstrated anticonvulsant effects in different models.
• Class III and IV AADs: Amiodarone, verapamil, and diltiazem exhibited anticonvulsant properties, though overdose or specific administration routes (e.g., intravenous esmolol, intra-arterial verapamil) can induce seizures.

Conclusions:

• AADs possess significant anticonvulsant potential, with varying efficacy across different drug classes and seizure types.
• AADs can potentiate the effects of AEDs, offering therapeutic advantages.
• Caution is necessary due to the proconvulsant risk of certain AADs at high doses or specific administration routes, necessitating careful patient management.